Open the map

IncyteINCY

Biotech & innovation · NASDAQ · USA

$112.75
Down 0.6% todayClose

Up 14.9% this year but −0.9% since June 26, behind the life science sector at +10.7%. Incyte supplies 1 mapped company and buys from 1.

Market cap
$22.5B
This year
+14.9%
1 year
+30.1%
P/E
14.0
P/S
3.9
P/B
3.5

Price vs the life science sector

since Jun 26INCYLife science sector, equal weight
Incyte (INCY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. INCY: −0.9% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+5%+10%+15%Jun 26AugSepOct 8INCY −0.9%Sector +10.7% Incyte (INCY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. INCY: −0.9% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+5%+10%+15%Jun 26AugSepOct 8INCY−0.9%Sector+10.7%

Supply chain

1 supplier · 1 customer
SUPPLIERS →→ CUSTOMERSCharles River Laboratories (CRL)CRLCharles River Labor…−0.8%Cencora (COR)CORCencora+1.3%INCYIncyte

Suppliers 1

Customers 1

Open the full chain →

About Incyte

Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.

Theme exposure

Oncology biotechOncologyInflammationDermatology

Products

  • Jakafi (myelofibrosis)
  • Opzelura (dermatology)
  • Oncology pipeline

Competitors

Risks

  • Jakafi concentration
  • Patent expiry

Same segment: Biotech & innovation

Innovation-driven biotech companies focused on novel treatment modalities. Segment 3 of 8 in the Medicine, pharma & life science value chain.

AmgenAMGN−1.4%Gilead SciencesGILD+0.2%Vertex PharmaceuticalsVRTX−0.5%ModernaMRNA+0.3%RegeneronREGN−0.3%BiogenBIIB−1.7%Alnylam PharmaceuticalsALNY+0.1%United TherapeuticsUTHR−2.2%

Compare INCY

Side by side with the largest companies in the same segment.

INCY vs AMGNINCY vs GILDINCY vs VRTXINCY vs MRNAINCY vs REGNINCY vs BIIB

See where Incyte sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →